
Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression (TRD), reported Microdose.
Assuming positive results, Compass will work with the FDA to help legalize psilocybin for TRD treatment, possibly as early as 2025.